Regeneron Pharmaceuticals (NASDAQ:REGN) Rating Reiterated by Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research report report published on Monday morning, Benzinga reports. The brokerage currently has a $925.00 price target on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on REGN. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an underperform rating in a research note on Friday. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an overweight rating in a research report on Wednesday, March 13th. Barclays increased their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an overweight rating in a research report on Tuesday, January 23rd. BMO Capital Markets increased their price target on Regeneron Pharmaceuticals from $1,055.00 to $1,082.00 and gave the stock an outperform rating in a research report on Monday, February 5th. Finally, Truist Financial reiterated a buy rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $970.57.

Regeneron Pharmaceuticals Trading Down 0.7 %

Shares of REGN opened at $898.56 on Monday. The company has a market capitalization of $98.63 billion, a P/E ratio of 25.86, a P/E/G ratio of 2.64 and a beta of 0.11. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $998.33. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.94 and a current ratio of 5.69. The stock has a 50-day moving average price of $956.81 and a 200 day moving average price of $889.95.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, beating analysts’ consensus estimates of $10.73 by $1.13. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm had revenue of $3.43 billion during the quarter, compared to the consensus estimate of $3.29 billion. During the same quarter in the prior year, the business posted $10.96 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up .6% on a year-over-year basis. Sell-side analysts forecast that Regeneron Pharmaceuticals will post 38.18 EPS for the current fiscal year.

Insider Transactions at Regeneron Pharmaceuticals

In other news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the sale, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the completion of the sale, the director now directly owns 18,382 shares in the company, valued at $17,540,472.04. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Andrew J. Murphy sold 5,783 shares of the firm’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The disclosure for this sale can be found here. Insiders sold a total of 13,729 shares of company stock valued at $13,124,641 in the last three months. 8.83% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors have recently bought and sold shares of the stock. Eudaimonia Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 1.2% in the fourth quarter. Eudaimonia Advisors LLC now owns 914 shares of the biopharmaceutical company’s stock valued at $803,000 after purchasing an additional 11 shares during the last quarter. Ronald Blue Trust Inc. grew its position in shares of Regeneron Pharmaceuticals by 18.8% in the third quarter. Ronald Blue Trust Inc. now owns 76 shares of the biopharmaceutical company’s stock valued at $63,000 after purchasing an additional 12 shares during the last quarter. Drive Wealth Management LLC grew its position in Regeneron Pharmaceuticals by 4.0% during the fourth quarter. Drive Wealth Management LLC now owns 311 shares of the biopharmaceutical company’s stock worth $273,000 after buying an additional 12 shares in the last quarter. MCF Advisors LLC grew its position in Regeneron Pharmaceuticals by 50.0% during the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after buying an additional 12 shares in the last quarter. Finally, LCM Capital Management Inc grew its position in Regeneron Pharmaceuticals by 2.5% during the fourth quarter. LCM Capital Management Inc now owns 486 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 12 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.